New drug aims to stop kidney rejection
NCT ID NCT07204080
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new medicine called TNX-1500 in 5 people who get a kidney transplant. The goal is to see if it is safe and can help prevent the body from rejecting the new kidney. Participants will be followed for one year to check for side effects and signs of rejection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the choice of anesthesia quiet the Body's surgical stress response?
- A simple blood test could spot kidney transplant rejection early
- Can your gut bacteria change how transplant drugs work?
- Can a new drug combo shield young hearts from transplant complications?
- A new drug combo may shield kidney transplant patients from a common viral threat
- Can one Mega-Dose of an antifungal beat a deadly infection in AIDS patients?